Eukaryotic DNA replication is tightly restricted to only once per cell cycle in order to maintain genome stability. Cells use multiple mechanisms to control the assembly of the prereplication complex (pre-RC), a process known as replication licensing. This review focuses on the regulation of replication licensing by posttranslational modifications of the licensing factors, including phosphorylation, ubiquitylation and acetylation. These modifications are critical in establishing the pre-RC complexes as well as preventing rereplication in each cell cycle. The relationship between rereplication and diseases, including cancer and virus infection, is discussed as well.
INTRODUCTION
In eukaryotic cells, the size of the genome ranges from~10 7 up to > 10 11 bp (Lewin, 2000) . Regardless of the size of the genome, all of the chromosomal DNA sequence must be precisely replicated once and only once in each cell cycle. Any genome over-or under-replication within a cell cycle will cause genome instability, which is the hallmark of cancer. To maintain genome integrity, cells have developed multiple mechanisms to assure a single duplication of the entire genome during each round of cell cycle. DNA replication starts at multiple sites on each chromosome, called origins. In budding and fission yeasts, the sixsubunit origin recognition complex (ORC) binds to chromatin throughout the cell cycle. In higher eukaryotes, however, ORC is released from chromatin in mitosis due to phosphorylation (for review, see DePamphilis, 2005; Arias and Walter, 2007) . Upon exit from mitosis, ORC recognizes and binds to the origins. It then recruits a protein called cell division cycle 6 (Cdc6) followed by the association of another DNA replication factor called Cdt1. These proteins form a platform that facilitates loading of the mini chromosome maintenance (MCM) 2-7 DNA helicase complex onto chromatin. Together, ORC, Cdc6, Cdt1 and MCM2-7 constitute the prereplication complex (pre-RC) (for review, see Bell and Dutta, 2002) . The process of pre-RC assembly on origins is also known as replication licensing, which is the key step in initiating DNA replication (Fig. 1) . Inactivation of these licensing factors is critical for preventing reinitiation of DNA replication from the origins in the rest of the cell cycle.
Although different organisms have evolved various mechanisms to prevent rereplication, essentially all mechanisms target pre-RC components, mainly Cdc6 and Cdt1 (for reviews, see DePamphilis et al., 2006; Arias and Walter, 2007; Hook et al., 2007) . In budding yeast, several independent pathways work redundantly to prevent relicensing in S, G2 and M phases. These pathways include downregulation of the level of Cdc6 by ubiquitin-mediated proteolysis and by inhibition of Cdc6 transcription; inactivation of Cdc6 and ORC proteins by binding of specific inhibitors; and nuclear export of Cdt1 and MCM complex (reviewed by Arias and Walter, 2007) . Phosphorylation of the pre-RC components by the cyclin dependent kinase (CDK) plays an essential role in regulating the pre-RC formation in budding yeast, which will be discussed later in this review.
In metazoans, Cdt1 is one of the major targets for prevention of rereplication. Unlike budding yeast, whose level of Cdt1 remains constant throughout the cell cycle, metazoan Cdt1 is negatively regulated by two ubiquitylation-mediated proteolysis pathways when cells progress into S phase ( Fig. 2) (Li et al., 2003; Zhong et al., 2003; Arias and Walter, 2005; Nishitani et al., 2006; . From late G1 to late M phase, Cdt1 is inactivated through interaction with a small protein, called geminin (Wohlschlegel et al., 2000; Tada et al., 2001) . The association of Cdt1 with geminin blocks the recruitment of MCM2-7, which in turn prevents pre-RC assembly, thereby prohibiting DNA replication licensing (Fig. 2 ) (for review, see Arias and Walter, 2007) . The binding of geminin also protects Cdt1 from ubiquitylation and proteolysis, ensuring that an adequate amount of Cdt1 is ready for replication licensing in the next round of cell cycle (Ballabeni et al., 2004) . Although Cdt1 is the primary target for regulating replication licensing in metazoans, there is evidence suggesting that both ORC and Cdc6 are also regulated by phosphorylation and ubiquitylation to prevent relicensing (Fig. 2) . Recently, a new MCM2-7 family member, MCM9, was found to be essential for MCM2-7 loading in vertebrates. MCM9 directly interacts with and positively regulates Cdt1 (Lutzmann and Mechali, 2008) . Hbo1 (histone acetyltransferase bound to Orc1) has been also shown to be crucial for MCM2-7 recruitment (Miotto and Struhl, 2008) . The requirement of Mcm9 and Hbo1 in pre-RC assembly adds an additional control on replication licensing in vertebrates (Fig. 1) .
Among the various regulatory pathways described above, posttranslational modifications of the licensing proteins and their regulators have been shown to play indispensible roles in preventing rereplication within a single cell cycle. The first part of this review summarizes the roles of protein phosphorylation, ubiquitylation and acetylation in regulating replication licensing. In the second part, we discuss how dysregulation of replication licensing is involved in diseases, such as cancer and virus infection, and the possibilities of aiming at the replication licensing system as therapeutic targets.
PHOSPHORYLATION REGULATES DNA REPLICATION LICENSING
Protein phosphorylation is a fundamental mechanism to assure proper progression of the cell cycle, including replication licensing. In fact, CDK activities play an essential role in controlling replication licensing in budding yeast, and almost every component of the pre-RC complex is subjected to phosphorylation regulation. For example, Orc2 and Orc6 are both phosphorylated by Cdc28/Cyclin B throughout the cell cycle, except in G1 phase (Nguyen et al., 2001 ). Cdc6 can be downregulated at the protein level by ubiquitylationand proteasome-mediated destruction when cells enter S phase (Drury et al., 1997) , which requires Cdc28-dependent phosphorylation of Cdc6 (Elsasser et al., 1999) . Cdc6 can also be inactivated by forming a stable complex with the CDK, Cdc28/Clb2, in G2 and M phases, and the interaction between Cdc6 and CDK depends on phosphorylation of the N-terminal domain of Cdc6 (Mimura et al., 2004) . Moreover, the MCM2-7 complex can be phosphorylated by Cdc28 and exported from the nucleus to the cytoplasm during S, G2 and M phases (Labib et al., 1999; Nguyen et al., 2000; Liku et al., 2005) . In metazoans, however, the regulation of ORC proteins and Cdc6 may be cell-type dependent. In Chinese hamster ovary cells (CHO), Orc1 can be phosphorylated by Cyclin A/Cdk1 during G2/M phase, which reduces its affinity for chromatin ; whereas in HeLa cells, phosphorylation of Orc1 by Cyclin A/Cdk2 directs Orc1 for SCF Skp2 -dependent proteolysis in S phase (Mendez et al., 2002) . Additionally, phosphorylation of Orc1 has been shown to direct the translocation of Orc1 into the cytoplasm and prevents pre-RC formation in both CHO and HeLa cells . In several types of human cells, a portion of Cdc6 is phosphorylated by Cyclin A/Cdk2 and the phosphorylation is required for nuclear export of Cdc6 in S phase to prevent rereplication ( Fig. 2) (Jiang et al., 1999; Petersen et al., 1999; Delmolino et al., 2001) . A similar phenomenon was also observed in C. elegans . In human cells, phosphorylation of Cdt1 by CDKs is required for the ubiquitylation-dependent degradation pathway that is controlled by the SCF Skp2 ubiquitin ligase ( Fig. 2 ) ( Liu et al., 2004; Sugimoto et al., 2004) . The role of phosphorylation in replication licensing control has also been extensively reviewed elsewhere (Bell and Dutta, 2002; Nishitani and Lygerou, 2002; DePamphilis et al., 2006; Arias and Walter, 2007; . In general, phosphorylation of licensing proteins exerts its regulatory function by targeting the proteins for ubiquitylation and subsequent proteolysis, by mediating interaction with specific inhibitors, or by directing translocation of the proteins to cytoplasm to prevent pre-RC formation.
UBIQUITYLATION CONTROLS DNA REPLICATION LICENSING
One efficient way to prevent DNA rereplication is to downregulate the pre-RC components via proteolysis. Most proteolysis in the cell occurs via the 26S proteasome which requires prior ubiquitylation of the target proteins. Ubiquitylation involves covalent attachment of ubiquitin to the target proteins via a cascade of three enzymes, including an activating enzyme E1, a conjugating enzyme E2 and a ubiquitin ligase E3 (Pickart, 2004) . Among the various E3 ligases, the Cullin-RING E3 superfamily (CRL) and the anaphase-promoting complex/cyclosome (APC/C) have been shown to play pivotal roles in DNA replication licensing control (Fig. 2) .
In human cells, cell cycle-regulated Cdt1 proteolysis is controlled by two different ubiquitylation pathways. The first pathway is mediated by the SCF Skp2 ubiquitin ligase, a Cullin1-RING E3 ligase (Li et al., 2003; Nishitani et al., 2006) . SCF Skp2 was shown to associate with and ubiquitylate Cdt1 in vivo. Overexpression of the substrate receptor Skp2 results in a decrease of Cdt1 protein levels, while knocking down of Skp2 by siRNA extends the half life of Cdt1 (Li et al., 2003) . As mentioned above, the SCF Skp2 -dependent ubiquitylation of Cdt1 occurs during S and G2 phases, and it depends on phosphorylation of Cdt1 by CDKs (Liu et al., 2004; Sugimoto et al., 2004; Takeda et al., 2005) . Interestingly, however, Cdt1 ubiquitylation via SCF Skp2 has only been observed in human cells thus far. Alternatively, Cdt1 can be destroyed by a Cullin4 and Cdt2 (CRL4 Cdt2 )-dependent pathway that is conserved from yeast to human (Hu et al., 2004; Jin et al., 2006; Lovejoy et al., 2006; Nishitani et al., 2006; Ralph et al., 2006; Sansam et al., 2006) . Unlike the SCF Skp2 -dependent pathway, the proteolysis of Cdt1 facilitated by CRL4 Cdt2 E3
ligase is restricted to S phase and requires chromatin-bound proliferating cell nuclear antigen (PCNA Chromatin ) Hu and Xiong, 2006; Senga et al., 2006) , indicating that Cdt1 destruction is coupled with DNA replication. The CRL4
Cdt2
-dependent proteolysis of Cdt1 is also activated when DNA damage occurs (Jin et al., 2006) . The two ubiquitylation pathways act independently to regulate the level of Cdt1 through the cell cycle and both contribute to DNA rereplication prevention.
The CDK inhibitor, p21, is also involved in regulating DNA replication licensing (Fig. 2) . As a CDK inhibitor, p21 protein plays multiple roles in many cellular processes. The best characterized function of p21 is to bind to and inhibit the activity of Cyclin/Cdk2 or Cyclin/Cdk4 complexes, which causes cell cycle arrest upon stress stimuli. It also interacts with PCNA and negatively regulates DNA replication and DNA repair (for review, see Prives and Gottifredi, 2008) . The level of p21 can be regulated at the transcriptional level as well as at the posttranscriptional level. It is well-known that p21 protein is subjected to proteasomeand ubiquitin-mediated degradation via the actions of the E3 ligases, including SCF Skp2 , APC/C, MDMX (Yu et al., 1998; Bornstein et al., 2003; Amador et al., 2007) and ubiquitinindependent, but proteasome-dependent pathway (Chen et al., 2007; Li et al., 2007) . Recently, three groups simultaneously found that p21 is also degraded via ubquitylation by CRL4 Cdt2 in human cells upon DNA damage treatment (Abbas et al., 2008; Nishitani et al., 2008) . This p21 degradation pathway is independent of the one mediated by SCF Skp2 (Abbas et al., 2008; Nishitani et al., 2008) , and ubiquitylation depends on the interaction between p21 and PCNA Chromatin , which is similar to the CRL4 Cdt2 -targeted degradation of Cdt1 (Abbas et al., 2008; Nishitani et al., 2008) . Kim and colleagues (2008) also showed that the DNA rereplication phenotype induced in Cdt2 knockdown cells can be abolished by co-silencing p21. This suggests that p21 contributes to the rereplication that occurs when Cdt2 is inactivated. A similar result was observed in C. elegans, in which Cul4-Ddb1 ubiquitylation pathway ubiquitylates CDK inhibitor, CKI-1, for degradation. Depletion of CKI-1 by RNAi can partially rescues the rereplication phenotype in a cul4 mutant . So, how does p21 regulate replication licensing? One possible downstream component of p21 in the licensing pathway is Cdc6. Previous studies indicated that Cdc6 is phosphorylated by CDK and can be exported to the cytoplasm in S and G2 phases in a phosphorylationdependent pathway (Jiang et al., 1999; Petersen et al., 1999; Delmolino et al., 2001) . Since stabilization of p21 by inactivation of Cdt2 causes a modest defect in nuclear export of Cdc6, p21 may contribute to replication licensing by inhibiting CDK activities that regulate Cdc6 localization by phosphorylation . Alternatively, considering that CDKs have many other cellular targets, p21 may also regulate replication licensing through other Cdc6-independent pathway. As mentioned above, both Cdt1 and p21 degradation requires direct interaction with PCNA Chromatin . This interaction is mediated through a consensus PCNA-binding motif, called the PIP box (Moldovan et al., 2007; Havens and Walter, 2009 ). However, the PIP box alone is not sufficient to recruit CRL4 Cdt2 to PCNA Chromatin , it also requires a positively charged amino acid at the +4 position in the PIP box which is conserved in human p21, Cdt1 and worm CKI-1 but not in other stable PIP box proteins (Havens and Walter, 2009 (Havens and Walter, 2009 ). This may reflect a common mechanism adopted by CRL4 Cdt2 ubiquitin ligase to specifically regulate the replication licensing system in a DNA synthesis-dependent manner. Geminin, the Cdt1 inhibitor, is regulated by ubiquitylation, too (Fig. 2) . It is a substrate of APC/C, another ubiquitin ligase that is a master regulator of the cell cycle (McGarry and Kirschner, 1998; Rape et al., 2006) . The activity of geminin oscillates conversely with the activity of APC/C. High activity of APC/C in late M phase and early G1 phase targets geminin for ubiquitylation-dependent proteolysis (McGarry and Kirschner, 1998) , allowing activation of Cdt1 for subsequent replication licensing. Inactivation of the APC/C E3 ligase by the inhibitor, Emi1, in S and G2 phase upregulates the level of geminin. As a consequence, the licensing function of Cdt1 is inhibited and origin refiring is prohibited (Fig. 2) (Hsu et al., 2002; Machida and Dutta, 2007) . Therefore, in addition to the CRL ligase family, APC/C ubiquitin ligase is also a key regulator of DNA replication licensing during cell division. The activation of APC/C in S phase can induce replication refiring. Indeed, knocking down Emi1 through RNA interference (RNAi) triggers massive rereplication that can be attenuated by the inactivation of APC/C by co-silencing Cdh1 and Cdc20 (Machida and Dutta, 2007) . Although Geminin is degraded through ubiquitylation by APC/C in mitosis, interestingly, not all geminin is degraded in late M phase. Li and Blow (2004) showed that a portion of polyubiquitylated geminin is inactivated but is not subjected to proteolysis. However, the mechanism is not clear.
In summary, ubiquitylation-dependent protein degradation plays essential roles in regulating DNA licensing. It controls DNA replication licensing either by adjusting the level of pre-RC components through direct ubiquitylation and degradation or by indirectly targeting upstream regulators according to the progression of the cell cycle.
ACETYLATION MEDIATES DNA REPLICATION LICENSING
Protein acetylation/deacetylation is a newly found mechanism involved in regulating the pre-RC components. A study published recently indicates that, in addition to phosphorylation and ubiquitylation, Cdc6 can also be acetylated by histone acetyltransferase (HAT) Gcn5 (Paolinelli et al., 2009) . In this study, Paolinelli and colleagues showed that Gcn5 interacts with Cdc6 and acetylates Cdc6 on lysine 92, 105 and 109 in vivo. Interestingly, the acetylation on these three lysine residues is required for phosphorylation on Ser 106 of Cdc6, a prerequisite for the cytoplasmic transportation and degradation of Cdc6. Further investigation demonstrated that acetylation of Cdc6 reduces its chromatin binding affinity and promotes S-phase progression. However, rereplication was not observed in cells expressing Cdc6 mutants that are either unable to be phosphorylated or acetylated (Paolinelli et al., 2009 ). This may be due to the fact that higher eukaryotic cells utilize multiple mechanisms to prevent rereplication (Arias and Walter, 2007) . It has been shown that overexpression of both Cdt1 and Cdc6 can induce rereplication (Yanow et al., 2001; Sugimoto et al., 2009 ). It would be interesting to investigate whether those Cdc6 mutants could trigger more profound rereplication phenotypes.
Another DNA replication licensing factor, Cdt1, is regulated by acetylation and deacetylation as well. HDAC11, the smallest member of the human histone deacetylase (HDAC) family, is shown to interact with Cdt1 directly (Glozak and Seto, 2009 ). The authors further showed that Cdt1 is acetylated and that acetylation may be catalyzed by lysine acetyltransferase 2B and 3B (KAT2B and KAT3B). Acetylation reduces Cdt1 ubiquitylation and protects Cdt1 from ubiquitylation and the subsequent proteolysis. Although the authors did not address whether acetylation of Cdt1 regulates replication licensing, one may speculate that hyperacetylation of Cdt1 may result in DNA rereplication. This remains to be tested in the future.
Furthermore, Cdt1 has been shown to interact with another histone acetyltransferase, Hbo1 (Miotto and Struhl, 2008) . It has long been known that Hbo1 interacts with both Orc1 and Mcm2 (Lizuka and Stillman, 1999; Burke et al., 2001) . There is also evidence suggesting that Hbo1 is required for the loading of MCM2-7 at the replication origins and positively regulates replication licensing (Lizuka et al., 2006) . However, the mechanism remained unknown. Recently, in studying how Hbo1 regulates replication licensing, Miotto and Struhl (2008) found that Hbo1 is recruited to the origins through direct interaction with Cdt1 in G1 phase (Fig. 1) . Moreover, the interaction between Cdt1 and Hbo1 is independent of geminin. While Hbo1 does not regulate the stability of Cdt1, it enhances rereplication induced by Cdt1 overexpression. Therefore, Hbo1 is believed to function as a coactivator of Cdt1. In support of this, an earlier study indicated that the acetytransferase activity of Hbo1 is required for MCM2-7 loading in both human cells and Xenopus egg extracts and that the replication defects in Xenopus egg extract depleted of Hbo1 could be rescued by adding excess Cdt1 (Lizuka et al., 2006) . However, in vitro experiment suggests that Cdt1 may not be acetylated by Hbo1 (Glozak and Seto, 2009 ). Instead, Miotto and Struhl (2010) further showed that Hbo1 acetylates histone H4 at the origins, and that this modification is required for MCM2-7 loading. Interestingly, although geminin does not interfere with the recruitment of Hbo1 by Cdt1, it inhibits Hbo1-dependent histone H4 acetylation at the origins, which prevents MCM2-7 loading (Miotto and Struhl, 2010) . Since hyperacetylated histone H4 correlates with an opened chromatin structure, the acetylation of histone H4 by Hbo1 may create a chromatin environment that favors the binding of MCM2-7 to the origin; alternatively, the acetylated histone H4 may create binding sites for some unidentified factors that is required for the loading of MCM2-7. These possibilities need to be tested in the future. Nonetheless, these data suggest that chromatin structure may play a direct role in regulation of replication licensing. It also suggests that geminin may inhibit the replication licensing through inhibition of histone H4 acetylation and the subsequent MCM2-7 loading.
REPLICATION LICENSING AND CANCER CHEMOTHERAPY
Proper control of replication licensing is essential for rereplication prevention and contributes to the maintenance of genome integrity. Therefore, it is not surprising that dysregulation of DNA replication licensing factors is associated with many human diseases, including cancers. Indeed, recent studies have shown that dysregulation of the pre-RC components as well as the upstream regulators is found in many types of cancer cells, such as breast, brain, prostate, oral, colorectal, ovarian, kidney, bladder, and hematological cancers (for reviews, see Gonzalez et al., 2005; Hook et al., 2007; Williams and Stoeber, 2007 ; and the included citations).
Multiple lines of evidence support the idea that overexpression of oncogenes can induce rereplication. Activation of the oncogene H-RasV12 in normal human cells induces DNA rereplication, which, in turn, triggers the DNA-damage checkpoint response and induces cellular senescence (Di Micco et al., 2006) . The cellular senescence results from the activation of DNA damage response triggered by Rasinduced DNA rereplication and the DNA hyper-replication is most likely due to the upregulation of Cdc6 by H-RasV12. Overexpression of cyclin E in U2OS cells results in elevated origin firing, an indication of DNA rereplication (Bartkova et al., 2006) . A nondegradable mutant allele of Cyclin D1, D1T286A, which is also refractory to nuclear export, inhibits the expression of Cullin4, thereby suppressing the ubiquitin ligase activity of CRL4
Cdt2
. As a result, the level of Cdt1 is upregulated and DNA rereplication occurs (Aggarwal et al., 2007) . Interestingly, Cyclin D1-induced rereplication is accelerated by inactivation of p53 (Aggarwal et al., 2007) , while p53 can prevent rereplication triggered by over-expressing both Cdt1 and Cdc6 (Vaziri et al., 2003) . However, it is unclear whether p53 plays any role in rereplication induced in Cdt2-silenced cells. Recent studies have suggested that pre-RC components themselves have oncogenic properties. For example, injection of NIH3T3 fibroblasts that overexpress Cdt1 into mice leads to the formation of tumors (Arentson et al., 2002) . Moreover, Cdt1 overexpression in T-cells lacking functional p53 results in lymphoblastic lymphoma (Seo et al., 2005) . Cdc6 has also been shown to have oncogenic properties (reviewed in Borlado and Mendez, 2008) .
Despite these observed oncogenic characteristics of DNA replication licensing factors, it is still not clear whether elevated levels of pre-RC components in cancer cells are results or causes of carcinogenesis. Nonetheless, DNA replication is becoming a potential target for cancer therapy. The rationale is that upregulation of DNA replication licensing usually leads to rereplication and genome instability, therefore renders cells more susceptible to drug treatments that target DNA damage response pathways. An interesting paper published recently suggests that geminin may be an effective target for cancer therapy (Zhu and Depamphilis, 2009) . In this study, the authors found that depletion of geminin in various cancer cells induced DNA rereplication and apoptosis, while depletion of geminin in normal cells had no effect on cell proliferation. As mentioned earlier, replication licensing is controlled by multiple mechanisms in normal cells, so that depletion of geminin alone is not able to induce rereplication. In some cancer cells, however, one or more pathways may be impaired due to the dysregulation of pre-RC components, therefore, depletion of geminin can be lethal.
Another promising cancer therapeutic target is the Cdc7 protein kinase which regulates the replication licensing components. Cdc7 is known to phosphorylate the MCM members and promote replication initiation and entry into S phase (Masai and Arai, 2002) . It also promotes pre-RC assembly by phosphorylating Mcm2 during cell cycle re-entry from quiescence (Chuang et al., 2009) . Depletion of Cdc7 prevents MCM loading and induces replication checkpoint response and cell cycle arrest in normal cells but not in cancer cells, leading the cancer cells to progress through a defective S phase and eventually undergo apoptosis (Montagnoli et al., 2004) . By taking advantage of this property of Cdc7, Montagnoli and colleagues (2008) found a small-molecule inhibitor of Cdc7, named PHA-767491 that preferentially induces apoptosis in cancer cell lines. This compound primarily targets Cdc7 and inhibits its kinase activity. Treating various cancer cell lines with PHA-767491 inhibits phosphorylation of MCM2-7 complex by Cdc7, prevents the initiation of DNA synthesis and results in apoptotic cell death, while treating primary fibroblasts with PHA-767491 only causes cell cycle arrest. In addition to PHA-767491, several other potent Cdc7 inhibitors have also been developed by a few pharmaceutical companies, and some of the inhibitors are currently under clinical trials (Swords et al., 2010) .
In summary, the discovery that targeting the DNA replication licensing system results in selective killing of cancer cells is novel and exciting. These findings greatly encourage development of novel anticancer drugs and may establish a new mode for chemotherapy.
VIRAL INFECTION DISRUPTS DNA REPLICATION LICENSING IN THE HOST CELLS
Most viruses reproduce themselves by utilizing the DNA replication machinery of the host cells. Recently, more and more evidence suggests that, while busily replicating themselves using the host replication machinery, several types of viruses also interfere with the DNA replication of the host cells.
Early studies on Simian virus 40 (SV40) found that infection of SV40 is able to induce cellular DNA synthesis in monkey kidney cells (Hatanaka and Dulbecco, 1966) and mouse 3T3 cells (Gershon et al., 1966) . It was later confirmed that SV40 infected cells escape cell cycle control and initiate multiple rounds of DNA replication within a single cycle, leading to endoreduplication of the host genome. The viral T antigen protein of SV40 is required for this endoreduplication phenotype (Friedrich et al., 1992 (Friedrich et al., , 1994 Perry and Lehman, 1998) . Recently, a study found that T antigen exerts its hyperreplication effect through targeting Nbs1, an essential protein that is involved in sensing DNA damage and suppressing inappropriate DNA rereplication in the cells . Another interesting study reported that, despite the fact that active rereplication occurs in SV40-infected monkey kidney cells, low levels of Mcm2 and Mcm3 were found to associate with the chromatin after cells passing through S phase, the same in uninfected cells. This suggests that reloading of MCM proteins to the chromatin is not required for SV40-induced rereplication of the host DNA, further indicating that novel cellular replication licensing pathway(s) may be activated when cells are infected by SV40 (Friedrich et al., 2005) .
Another example of virus infection regulating host DNA replication licensing comes from research on hepatitis B virus (HBV). HBV is known to cause hepatitis and hepatocellular carcinoma (Beasley et al., 1981) . The HBV X (HBX) protein, which is essential for viral replication (Zoulim et al., 1994) , regulates gene expression as well as other cellular processes (Andrisani and Barnabas, 1999; Bouchard and Schneider, 2004) . Recently, Rakotomalala and colleagues (2008) indentified a new function of HBX in regulating replication licensing in the host cells. They found that expression of HBX in an immortalized mouse hepatocyte cell line induced DNA rereplication. Further study demonstrated that expression of HBX resulted in elevated level of Cdt1 and Cdc6, while the level of geminin was downregulated. Perturbation of the balance between Cdt1 and geminin by HBX may be a direct cause of DNA rereplication in this case. Although the authors did not address how HBX deregulates the licensing factors, the significantly altered mRNA levels of Cdt1, Cdc6 and geminin suggest that HBX may exert its effect by regulating transcription of these genes (Rakotomalala et al., 2008) . Alternatively, the fact that HBX is able to interact with Ddb1, a common linker protein in the CUL4 ubiquitin complex, and disrupt CRL4
Cdt2 ubiquitin ligase-mediated proteolysis pathway (Bontron et al., 2002) , suggests that HBX may induce rereplication by preventing degradation of Cdt1 and p21, which are both over-produced when CRL4 Cdt2 is inactivated (Jin et al., 2006; . Viruses may also interfere with their host cells by inhibiting cellular DNA replication. For example, human cytomegalovirus (HCMV) was shown to inhibit G1/S progression and cellular DNA synthesis (Bresnahan et al., 1996; Lu and Shenk, 1996; Dittmer and Mocarski, 1997) . In HCMV infected human fibroblast cells, Cdt1 is downregulated and the expression of MCM proteins is delayed; whereas Cdc6 and geminin are both upregulated. The pre-RC assembly is blocked at the step of MCM loading (Biswas et al., 2003) . These data suggest that HCMV suppresses cellular DNA synthesis by impairing replication licensing. Consistent with these results, HCMV infection also leads to inactivation of the APC Cdh1 E3 ligase, resulting in accumulation of Cdc6 and geminin (Tran et al., 2008) . These data partially explain how HCMV infection inhibits DNA synthesis of the host cells. A similar inhibitory effect of host cell DNA replication was also detected with the human papillomavirus (HPV) E4 protein, which prevents MCM loading to the pre-RC complex by functioning together with Cdc6 through an unknown mechanism (Roberts et al., 2008) . Interference with host cell DNA replication by viruses is not limited to mammalian cells. A recent study found that the plant geminivirus rep protein can induce rereplication when introduced into fission yeast (Kittelmann et al., 2009 ). Since it is believed that disruption of host cell DNA replication may help divert the host cell machinery toward viral replication, understanding how virus infection disrupts host DNA replication licensing system may contribute to the development of new treatments for virus infection.
CONCLUSION
Proper regulation of DNA replication licensing is crucial to the fate of cells. Thus far, large efforts have been devoted to understand the mechanisms of how cells regulate replication licensing and prevent DNA rereplication within a single cell cycle. These mechanisms can be classified in three categories: inhibiting the activities of licensing proteins through posttranslational modifications or inhibitor binding, unloading the licensing proteins from chromatin, and downregulating the level of the licensing proteins when cells exit S phase. Posttranslational modifications, including phosphorylation, ubiquitylation and acetylation, have been shown to play important roles in executing these mechanisms. In the future, it would be interesting to investigate whether other types of protein modification, such as methylation and SUMOylation, are involved in regulation of replication licensing. On the other hand, with the discovery of new factors (such as Mcm9, p21 and Hbo1) that are involved in licensing regulation, one can envision that additional pathways remain to be uncovered. Since dysregulation of the licensing process is tightly linked to tumorigenesis and virus infection, understanding cellular mechanisms that regulate DNA replication licensing will greatly benefit the chemotherapies of human diseases.
